Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Potential Impact of Atelectasis and Primary Tumor Glycolysis on F-18 FDG PET/CT on Survival in Lung Cancer Patients

  • Hasbek, Zekiye (Department of Nuclear Medicine, Faculty of Medicine, Cumhuriyet University) ;
  • Yucel, Birsen (Department of Radiation Oncology, Faculty of Medicine, Cumhuriyet University) ;
  • Salk, Ismail (Department of Radiology, Faculty of Medicine, Cumhuriyet University) ;
  • Turgut, Bulent (Department of Nuclear Medicine, Faculty of Medicine, Cumhuriyet University) ;
  • Erselcan, Taner (Department of Nuclear Medicine, Faculty of Medicine, Cumhuriyet University) ;
  • Babacan, Nalan Akgul (Department of Medical Oncology, Pendik Training and Research Hospital, Marmara University) ;
  • Kacan, Turgut (Department of Medical Oncology, Faculty of Medicine, Cumhuriyet University)
  • Published : 2014.05.15
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Atelectasis is an important prognostic factor that can cause pleuritic chest pain, coughing or dyspnea, and even may be a cause of death. In this study, we aimed to investigate the potential impact of atelectasis and PET parameters on survival and the relation between atelectasis and PET parameters. Materials and Methods: The study consisted of patients with lung cancer with or without atelectasis who underwent $^{18}F$-FDG PET/CT examination before receiving any treatment. $^{18}F$-FDG PET/CT derived parameters including tumor size, SUVmax, SUVmean, MTV, total lesion glycosis (TLG), SUV mean of atelectasis area, atelectasis volume, and histological and TNM stage were considered as potential prognostic factors for overall survival. Results: Fifty consecutive lung cancer patients (22 patients with atelectasis and 28 patients without atelectasis, median age of 65 years) were evaluated in the present study. There was no relationship between tumor size and presence or absence of atelectasis, nor between presence/absence of atelectasis and TLG of primary tumors. The overall one-year survival rate was 83% and median survival was 20 months (n=22) in the presence of atelectasis; the overall one-year survival rate was 65.7% (n=28) and median survival was 16 months (p=0.138) in the absence of atelectasis. With respect to PFS; the one-year survival rate of AT+ patients was 81.8% and median survival was 19 months; the one-year survival rate of AT-patients was 64.3% and median survival was 16 months (p=0.159). According to univariate analysis, MTV, TLG and tumor size were significant risk factors for PFS and OS (p<0.05). However, SUVmax was not a significant factor for PFS and OS (p>0.05). Conclusions: The present study suggested that total lesion glycolysis and metabolic tumor volume were important predictors of survival in lung cancer patients, in contrast to SUVmax. In addition, having a segmental lung atelectasis seems not to be a significant factor on survival.

Keywords

References

  1. Abd El-Hafez YG, Moustafa HM, Khalil HF, et al (2013). Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma. Oral Oncol, 49, 261-8. https://doi.org/10.1016/j.oraloncology.2012.09.005
  2. Abramyuk A, Appold S, Zophel K, et al (2012). Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non-small cell lung cancer scheduled for radiotherapy-a retrospective study. Lung Cancer, 78, 148-52. https://doi.org/10.1016/j.lungcan.2012.08.001
  3. Arslan N, Tuncel M, Kuzhan O, et al (2011). Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer. Ann Nucl Med, 25, 406-13. https://doi.org/10.1007/s12149-011-0478-y
  4. Bille A, Okiror L, Skanjeti A, et al (2013). The prognostic significance of maximum standardized uptake value of primary tumor in surgically treated non-small-cell lung cancer patients: analysis of 413 cases. Clin Lung Cancer, 14, 149-56. https://doi.org/10.1016/j.cllc.2012.04.007
  5. Bulbul Y, Oztuna F, Topbas M, Ozlu T (2005). Survival analyses of patients with thoracic complications secondary to bronchial carcinoma at the time of diagnosis. Respiration, 72, 388-94. https://doi.org/10.1159/000086253
  6. Bulbul Y, Eris B, Orem A, et al (2010). Pulmonary atelectasis and survival in advanced non-small cell lung carcinoma. Ups J Med Sci, 115, 176-80. https://doi.org/10.3109/03009731003695624
  7. Chen C, Zheng H, Gao W, et al (2010). Prognosis and staging of superficial endobronchial lung cancer: the impact of invasion depth, tumor diameter, and coexistent pneumonitis or atelectasis. Chin Med J, 123, 1505-9.
  8. Cheng NM, Chang JT, Huang CG, et al (2012). Prognostic value of pretreatment $^{18}F$-FDG PET/CT and human papillomavirus type 16 testing in locally advanced oropharyngeal squamous cell carcinoma. Eur J Nucl Med Mol Imaging, 39, 1673-84. https://doi.org/10.1007/s00259-012-2186-9
  9. Cho A, Hur J, Kang WJ, et al (2011). Usefulness of FDG PET/CT in determining benign from malignant endobronchial obstruction. Eur Radiol, 21, 1077-87. https://doi.org/10.1007/s00330-010-2006-1
  10. Dediu M, Crisan E, Radut M, et al (2009). The favorable prognostic significance of atelectasis in patients with advanced non-small cell lung cancer: results of a prospective observational study. Lung Cancer, 63, 271-6. https://doi.org/10.1016/j.lungcan.2008.05.007
  11. De Leyn P, Lardinois D, Van Schil PE, et al (2007). ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothor Surg, 32, 1-8. https://doi.org/10.1016/j.ejcts.2007.01.075
  12. Ding XP, Zhang J, Li BS, et al (2012). Feasibility of shrinking field radiation therapy through $^{18}F$-FDG PET/CT after 40 Gy for stage III non-small cell lung cancers. Asian Pac J Cancer Prev, 13, 319-23. https://doi.org/10.7314/APJCP.2012.13.1.319
  13. Gerbaudo VH, Julius B (2007). Anatomo-metabolic characteristics of atelectasis in F-18 FDG-PET/CT imaging. Eur J Radiol, 64, 401-5. https://doi.org/10.1016/j.ejrad.2007.08.013
  14. Lee P, Weerasuriva DK, Lavori PW, et al (2007). Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys, 69, 328-33. https://doi.org/10.1016/j.ijrobp.2007.04.036
  15. Liao S, Penney BC, Zhang H, et al (2012). Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in stage IV nonsurgical small-cell lung cancer. Acad Radiol, 19, 69-77. https://doi.org/10.1016/j.acra.2011.08.020
  16. Liu FY, Chao A, Lai CH, et al (2012). Metabolic tumor volume by 18F-FDG PET/CT is prognostic for stage IVB endometrial carcinoma. Gynecol Oncol, 125, 566-71. https://doi.org/10.1016/j.ygyno.2012.03.021
  17. Moon SH, Choi JY, Lee HJ, et al (2013). Prognostic value of 18F- FDG PET/CT in patients with squamous cell carcinoma of the tonsil: comparisons of volume-based metabolic parameters. Head Neck, 35, 15-22. https://doi.org/10.1002/hed.22904
  18. Mutlu H, Buyukcelik A, Erden A, et al (2013). Staging with PET-CT in patients with locally advanced non small cell lung cancer is superior to conventional staging methods in terms of survival. Asian Pac J Cancer Prev, 14, 3743-6. https://doi.org/10.7314/APJCP.2013.14.6.3743
  19. Obara P, Pu Y (2013). Prognostic value of metabolic tumor burden in lung cancer. Chin J Cancer Res, 25, 615-22.
  20. Ou SH, Zell JA, Ziogas A, Anton-Culver H (2008). Prognostic significance of the non-size-based AJCC T2 descriptors: visceral pleura invasion, hilar atelectasis, or obstructive pneumonitis in stage IB non-small cell lung cancer is dependent on tumor size. Chest, 133, 662-9. https://doi.org/10.1378/chest.07-1306
  21. Pauwels EK, Coumou AW, Kostkiewicz M, Kairemo K (2013). [F]Fluro-2-Deoxy-D-Glucose positron emission tomography/computed tomography imaging in oncology: initial staging and evaluation of cancer therapy. Med Princ Pract, 22, 427-37. https://doi.org/10.1159/000346303
  22. Roedl JB, Colen RR, Holalkere NS, et al (2008). Adenocarcinomas of the esophagus: response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PET-CT. Comparison to histopathologic and clinical response evaluation. Radiother Oncol, 89, 278-86. https://doi.org/10.1016/j.radonc.2008.06.014
  23. Sahin F, Yildiz P (2011). Radiological, bronchoscopic and histopathologic characteristics of patients with primary lung cancer in Turkey (2006-2009). Asian Pac J Cancer Prev, 12, 1947-52.
  24. Shyn PB (2013). Interventional positron emission tomography/computed tomography: state-of-the-art. Tech Vasc Interv Radiol, 6, 182-90.
  25. Yin LJ, Yu XB, Ren YG, et al (2013). Utilization of PET-CT in target volume delineation for three-dimensional conformal radiotherapy in patients with non-small cell lung cancer and atelectasis. Multidiscip Respir Med, 8, 21. https://doi.org/10.1186/2049-6958-8-21
  26. Zaizen Y, Azuma K, Kurata S, et al (2012). Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy. Eur J Radiol, 81, 4179-84. https://doi.org/10.1016/j.ejrad.2012.07.009
  27. Zhang H, Wroblewski K, Appelbaum D, Pu Y (2013). Independent Prognostic Value of Whole-body Metabolic Tumor Burden from FDG-PET in Non-Small Cell Lung Cancer. Int J Comput Assist Radiol Surg, 8, 181-91.
  28. Zhu SH, Zhang Y, Yu YH, et al (2013). FDG PET-CT in non-small cell lung cancer: relationship between primary tumor FDG uptake and extensional or metastatic potential. Asian Pac J Cancer Prev, 14, 2925-9. https://doi.org/10.7314/APJCP.2013.14.5.2925

Cited by

  1. Differences in the Prognostic Significance of the SUVmax between Patients with Resected Pulmonary Adenocarcinoma and Squamous Cell Carcinoma vol.15, pp.23, 2014, https://doi.org/10.7314/APJCP.2014.15.23.10171
  2. Comparison of Metabolic and Anatomic Response to Chemotherapy Based on PERCIST and RECIST in Patients with Advanced Stage Non-small Cell Lung Cancer vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.321
  3. Importance of PET/CT Scan Use in Planning Radiation Therapy for Lymphoma vol.16, pp.5, 2015, https://doi.org/10.7314/APJCP.2015.16.5.2051